- First quarter revenues were $3.1 million -- Net loss per share was $0.26 for the quarter -- Excluding special items, net loss per share was $0.21 for the quarter* -- Acquisition of Baxano, Inc. and financing transaction expected to close May 31 -
RALEIGH, N.C., May 9, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device compan...
RALEIGH, N.C., April 26, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that it plans to release first quarter 2013 financial and operating results, and provide an update on the company's acquisition of Baxano, Inc. ("Baxano"), after market close on Thursday, May 9, 2013. Ken Reali, President and Chief Executive Officer of TranS...
RALEIGH, N.C., March 14, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that it will participate in the Canaccord Genuity Musculoskeletal conference in March.
Ken Reali, President and Chief Executive Officer, and Joe Slattery, Executive Vice President and Chief Financial Officer, are scheduled to present at the Canaccord Gen...
- Fourth quarter revenues were $4.1 million -- Net loss per share was $0.44 for the quarter —- Excluding special items, net loss per share was $0.20 for the quarter* -
RALEIGH, N.C., March 4, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products to treat degene...
Conference Call to be Held on March 4, 2013 at 8:30 a.m. ESTCombination Adds Rapidly Growing Minimally Invasive Spinal Decompression Technology and Large Surgeon User BaseBaxano Shareholders Commit $15.3M in Concurrent Financing
RALEIGH, N.C., March 4, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on desig...
WILMINGTON, N.C., Feb. 21, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that it will participate in two healthcare conferences in February and March, 2013.
Ken Reali, President and Chief Executive Officer, and Joe Slattery, Executive Vice President and Chief Financial Officer, are scheduled to attend the Lazard Snowbird Me...
WILMINGTON, N.C., Feb. 20, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that it plans to release fourth quarter 2012 financial and operating results after market close on Monday, March 4, 2013. Ken Reali, President and Chief Executive Officer of TranS1, and Joe Slattery, Chief Financial Officer, will host a conference call sta...
WILMINGTON, N.C., Feb. 19, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing spine products to treat degenerative conditions of the spine affecting the lumbar region, announced today that it has appointed Mark Stautberg to serve on its Board of Directors. Mr. Stautberg has ov...
WILMINGTON, N.C., Feb. 11, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lumbar region, announced today that the company estimates that the total number of commercial and Federal Government lives covered...
WILMINGTON, N.C., Jan. 14, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lower lumbar region, today announced its preliminary unaudited revenue for the fourth quarter ended December 31, 2012.
TranS1 ...
WILMINGTON, N.C., Dec. 27, 2012 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lower lumbar region, today announced that it had reached a tentative agreement in principle with the U.S. Department of Justice re...
WILMINGTON, N.C., Nov. 14, 2012 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that Ken Reali, President and Chief Executive Officer, and Joe Slattery, Executive Vice President and Chief Financial Officer, are scheduled to present at the 2012 Piper Jaffray Healthcare Conference in New York, NY on Wednesday, November 28, 2012 at 2:00 ...
- Third Quarter Revenues Were $3.2 Million -- Net Loss Per Share Was $0.22 for the Quarter -
WILMINGTON, N.C., Nov. 8, 2012 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lower lumbar region, today announc...
WILMINGTON, N.C., Nov. 2, 2012 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region, announced today that the Department of Health and Human Services, thro...
WILMINGTON, N.C., Nov. 1, 2012 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that Ken Reali, President and Chief Executive Officer, and Joe Slattery, Executive Vice President and Chief Financial Officer, are scheduled to present at the 2012 Lazard Capital Markets Healthcare Conference in New York, NY on Wednesday, November 14, 2012 ...
WILMINGTON, N.C., Oct. 25, 2012 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that it plans to release third quarter 2012 financial and operating results after market close on Thursday, November 8, 2012. Ken Reali, President and Chief Executive Officer of TranS1 and Joe Slattery, Chief Financial Officer, will host a conference call ...
WILMINGTON, N.C., Oct. 10, 2012 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lower lumbar region, announced today the signing of a distribution agreement with Beijing Jiade Sunshine ("Jiade").
The distri...
WILMINGTON, N.C., Sept. 17, 2012 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lower lumbar region, is pleased to announce the appointment of Stephanie M. Fitts, Ph.D. as Vice President of Regulatory, Quality...
WILMINGTON, N.C., Aug. 28, 2012 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that Ken Reali, President and Chief Executive Officer, and Joe Slattery, Executive Vice President and Chief Financial Officer, are scheduled to present at the 2012 Stifel Nicolaus Healthcare Conference in Boston, MA on Wednesday, September 5, 2012 at 10:55...
- Second Quarter Revenues Were $3.5 Million -- Net Loss per Share Was $0.23 for the Quarter -
WILMINGTON, N.C., Aug. 9, 2012 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lower lumbar region, today announ...
